Exact Sciences Earnings Reports

Exact Sciences delivered a strong third quarter in 2025, achieving record total revenue of $851 million, a 20% increase year-over-year. The company also reported a significant improvement in net loss and a substantial increase in adjusted EBITDA and free cash flow. Key to their growth was the performance of their Screening and Precision Oncology segments, alongside the launch of their new multi-cancer early detection test, Cancerguard.

Exact Sciences delivered a strong second quarter in 2025, achieving record total revenue of $811 million, a 16% increase year-over-year. The company also significantly improved its adjusted EBITDA to $138 million, up 26%, and narrowed its net loss to $1 million. This performance was driven by robust growth in both Screening and Precision Oncology segments, and the successful launch of Cologuard Plus.

Exact Sciences delivered solid Q1 2025 performance with 11% revenue growth, improved profitability metrics, and the launch of two key diagnostic products, despite continuing to report a net loss.

Exact Sciences achieved 10% YoY revenue growth in Q4 2024, reaching $713.42M. Screening revenue grew by 14%, while Precision Oncology revenue remained flat. However, an $838M impairment charge led to a substantial net loss of $864.59M, significantly higher than the prior year's loss of $49.77M. Adjusted EBITDA improved to $75.38M with an 11% margin.

Exact Sciences Corp. reported a 13% increase in total revenue to $709 million for Q3 2024, driven by growth in both Screening and Precision Oncology segments. The company achieved significant improvements in profitability, with adjusted EBITDA reaching $99 million and an adjusted EBITDA margin of 14%.

Exact Sciences Corp. announced strong second-quarter results, with a 12% increase in total revenue to $699 million. The company screened over 1 million people with Cologuard for the first time in a quarter and advanced its pipeline. Full-year revenue guidance was maintained, and adjusted EBITDA guidance was raised.

Exact Sciences announced first-quarter 2024 results with a total revenue of $638 million, a 6% increase compared to the same period in 2023. The company maintains its full-year 2024 revenue and adjusted EBITDA guidance.

Exact Sciences Corp. reported a revenue of $647 million for the fourth quarter of 2023 and $2.50 billion for the full year of 2023. The company also generated positive free cash flow during the quarter.

Exact Sciences reported a 20% increase in total revenue to $628.3 million for the third quarter of 2023. The company delivered over 1 million test results and raised its full-year revenue and adjusted EBITDA guidance.

Exact Sciences Corp. announced strong second-quarter results with a 19% increase in total revenue to $622.1 million. The company generated positive free cash flow and raised its full-year revenue and adjusted EBITDA guidance.

Exact Sciences Corp. announced strong first-quarter results with a 24% increase in total revenue to $602.5 million. The company raised its full-year revenue guidance by $110 million at the midpoint and expects to turn free cash flow positive during 2023, ahead of the previous target of 2024.

Exact Sciences reported a 17% increase in total revenue for Q4 2022, reaching $553 million. Screening revenue was $404 million and Precision Oncology revenue was $143 million. The company anticipates revenue of $2,265-$2,315 million and positive adjusted EBITDA for full year 2023.

Exact Sciences Corp. generated revenue of $523 million for the third quarter ended September 30, 2022, compared to $456 million for the same period of 2021. The company raised full-year revenue guidance and lowered operating expense guidance. Adjusted EBITDA profitability is now expected in the third quarter of 2023.

Exact Sciences Corp. announced second-quarter revenue of $521.6 million, a 20% increase compared to the same period in 2021. Screening revenue increased by 34%, while Precision Oncology revenue increased by 12%. The company is focused on expanding testing, prioritizing profitability, and generating evidence for its cancer diagnostic pipeline.

Exact Sciences Corp. announced first quarter 2022 results with a total revenue of $486.6 million, a 21% increase compared to the same period in 2021. The growth was primarily driven by a 28% increase in Screening revenue and an 18% increase in Precision Oncology revenue. The company is focused on expanding its cancer diagnostics and treatment solutions.

Exact Sciences reported Q4 2021 revenue of $473.8 million, a 2% increase compared to Q4 2020. Screening revenue increased by 11%, and Precision Oncology revenue increased by 27%. The company's net loss was $220.6 million, an improvement compared to the net loss of $418.3 million in the same period of the previous year.

Exact Sciences reported Q3 2021 revenue of $456.4 million, a 12% increase compared to Q3 2020. Screening revenue increased by 31% to $280.4 million, and Precision Oncology revenue increased by 59% to $145.4 million. The company's net loss was $166.9 million, or $0.97 per share, compared to a net loss of $202.5 million, or $1.35 per share in the same period of 2020.

Exact Sciences Corp. announced revenue of $434.8 million for the second quarter ended June 30, 2021, compared to $268.9 million for the same period of 2020. The company reported a net loss of $176.9 million, or $1.03 per share, compared to a net loss of $68.1 million, or $0.45 per share for the same period of 2020.

Exact Sciences reported a revenue of $402.1 million for the first quarter ended March 31, 2021, representing a 16% increase compared to the $347.8 million reported for the same period in 2020. The company's screening and precision oncology segments showed growth, and they anticipate revenue of $1,690-$1,735 million during 2021.

Exact Sciences Corp. announced Q4 2020 revenue of $466.3 million and full year revenue of $1,491.4 million. The company's performance was driven by its Cologuard and Oncotype tests. The company reported a net loss of $(436.8) million, or $(2.79) per share, and adjusted EBITDA of $87.9 million.

Exact Sciences Corp. announced strong Q3 2020 results, with revenue reaching $408.4 million, compared to $218.8 million in Q3 2019. The company saw growth in Precision Oncology and COVID-19 testing, while also managing an intangible asset impairment charge. They are confident in the long-term growth outlook for Cologuard and Oncotype DX and are excited about the liquid biopsy tests pipeline.

Exact Sciences Corp. reported revenue of $268.9 million for the second quarter ended June 30, 2020, compared to $199.9 million for the same period of 2019. Screening revenue decreased by 34 percent, while Precision Oncology and COVID-19 testing contributed $103.0 million and $34.6 million, respectively. The company's net loss was $86.1 million, or $0.58 per share.

Exact Sciences Corp. reported revenue of $347.8 million for the first quarter ended March 31, 2020, compared to $162.0 million for the same period of 2019. The company's screening revenue was $219.5 million, an increase of 35 percent, while precision oncology revenue was $128.4 million. The net loss was $105.7 million, or $0.71 per share.

Exact Sciences Corp. reported a strong fourth quarter with a total revenue of $295.6 million and a net income of $77.9 million. Screening revenue increased by 60%, and Precision Oncology revenue was $66.2 million. The company's adjusted EBITDA was $9.7 million.